Background: Novel Coronavirus Disease 2019 (COVID-19) has affected more than 89 million people worldwide . As the pandemic rages on, more complications of the disease are recognized including stroke, cardiovascular disease, thromboembolic events, encephalopathy, seizures and more . Peripheral nervous system involvement, particularly Guillain-Barre Syndrome (GBS) are of special interest given the increasing reports of cases related to COVID-19 . Because of the potentially delayed onset of symptoms polyradiculoneuropathy and weakness after the traditional COVID-19 symptoms, it is vitally important for emergency physicians to be vigilant and consider this as part of their differential diagnosis . GBS usually occurs after an infectious insult, and a variety of culprit pathogens have been identified in the literature . Case Report: We describe a case of 35-year-old man who developed GBS after being diagnosed with COVID-19 infection . The patient displayed classic symptoms of neuropathy, areflexia, and lower extremity weakness . CSF evaluation demonstrated albuminocytologic dissociation seen in GBS, though anti-ganglioside autoantibodies were negative . These antibodies are often negative and thus do not exclude the diagnosis . The patient responded clinically to intravenous immunoglobulin therapy and was discharged home . Why Should an Emergency Physician Be Aware of This?: This case report contributes to further evidence that COVID-19 joins other organisms as causes of GBS . ED physicians are the first point of contact for many patients . Increased awareness of this complication of COVID-19 will lead to higher detection . Prompt recognition could lead to speedier and more complete neurologic recovery of affected patients.